Italy addresses "50% lifetime cancer risk"
This article was originally published in Clinica
Executive Summary
As the latest cancer data for Italy point at a 50% lifetime risk of the disease, an initiative is underway to harmonise data collection nationally. In a bid to tackle the burgeoning rise in incidence, the national cancer registries association (AIRTUM), backed by the government, will seek to reduce wide variations in data quality between southern, northern and central Italy.
You may also be interested in...
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.
CDS Final Guidance Draws More Criticism, This Time From Congress
Senator Bill Cassidy says FDA “disregarded” Congressional intent by expanding its authority to regulate clinical decision support software.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.